Tag Archives: GW Pharma

November, 2018

September, 2018

  • 27 September

    DEA Reschedules GW Pharma’s Epidiolex (cannabidiol) Oral Solution to Schedule V

    LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral …

April, 2018

January, 2018

May, 2017

February, 2017

  • 7 February

    GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

    London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …

June, 2016

  • 27 June

    GW Pharma’s Epidiolex Succeeds in Late-Stage Lennox-Gastaut Syndrome Study

    LONDON, June 27, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its …

April, 2016

March, 2016